The promises and challenges of neoantigen cancer vaccines - PubMed
12 hours ago
- #immunotherapy
- #neoantigen
- #cancer-vaccines
- Neoantigen cancer vaccines leverage genomic sequencing and improved HLA epitope prediction for clinical development.
- Early trials show neoantigen vaccines can induce durable T cell immunity lasting decades.
- mRNA vaccines, initially for cancer, show promise due to efficacy and scalable production, as seen in COVID-19.
- Optimal vaccine platform and delivery strategy remain uncertain; lipid-based formulations may enhance immunogenicity.
- Current state and future advancements in neoantigen vaccines are reviewed, highlighting clinical progress and opportunities.